Therefore, to identify novel compounds which act synergistically with SAHA, we performed a cell-based, high-throughput drug screen using a MYC-expressing breast cancer cell line (MDA-MB-231) [19] with relatively high resistance to SAHA (IC50 4.6 μM) compared to neuroblastoma cell lines. The gene discussed is MYC; the disease is breast carcinoma.